ArticleThe Indian journal of medical research2026
Therapeutic role of deferasirox loaded niosomes against aluminium-maltolate induced Alzheimer disease: A study in Swiss albino mice.
Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Aluminium, a common component in underarm deodorants, has been reported to increase oxidative stress when present in the bloodstream, and chronic exposure is considered a potential risk factor for Alzheimer disease. This study investigates the neuroprotective and chelating effects of deferasirox (DFX) and its niosome-based formulation (DFX-NS) against aluminium-maltolate (Almal)-induced neurotoxicity in mice. Methods Thirty male Swiss albino mice were randomly assigned into five groups: Control, Almal, Standard (STD), DFX, and DFX-NS. For 21 d, all groups except the control received Almal to induce neurotoxicity, followed by respective treatments for an additional 21 d. After the treatment period, cognitive function was assessed using behavioral tests such as the Morris Water Maze and Y Maze. An in vitro MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed on SH-SY5Y cells to evaluate the neuroprotective potential of DFX. In vivo analyses-including elemental analysis (ICP-MS), histopathology, oxidative stress parameters [Reactive Oxygen Species (ROS), Malondialdehyde (MDA), Catalase (CAT)], urine analysis, and protein estimation (Bradford assay)-were performed on the brain, which was isolated after cervical dislocation. Results The results obtained shows that the Deferasirox has optimum capacity to chelate the aluminium ions in the brains of the Alzheimer-diseased swiss albino mice. Though, the evidence obtained were not fully conclusive, but still the results from the niosomes group shows effective treatment option for the Alzheimer disease caused by the aluminium exposure. Interpretation and conclusions The efficacy of DFX and DFX-NS in reducing aluminium-induced neurotoxicity and oxidative stress in the brain proves that DFX could be a possible candidate for treating Alzheimer's patients linked with metal toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.